Developing 68Ga-Labeled Exendin(9-39) Derivatives for PET Imaging of Insulinomas

Tuo Li1, Linlin Li1, Yaping Luo1

  • 1Department of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing 100730, China.

Bioconjugate Chemistry
|November 8, 2025
PubMed

Insights

Researchers developed a novel Gallium-68 labeled tracer, [68Ga]Ga-E09, for imaging glucagon-like peptide-1 receptor (GLP-1R) positive tumors. This safer antagonist tracer shows superior tumor uptake and binding affinity compared to previous agents.

Area of Science:

  • Nuclear Medicine
  • Radiopharmaceutical Chemistry
  • Molecular Imaging

Background:

  • Glucagon-like peptide-1 receptor (GLP-1R) is highly expressed in insulinomas, making it a key target for diagnostic imaging.
  • Current GLP-1R agonist tracers can cause adverse effects like hypoglycemia, especially in pediatric patients.

Purpose of the Study:

  • To design and develop novel, safer GLP-1R antagonist radiotracers for improved insulinoma imaging.
  • To evaluate the performance of these new tracers using computational and experimental methods.

Main Methods:

  • Utilized molecular dynamics (MD) simulations and MM/GBSA calculations to predict binding affinities of NOTA-conjugated exendin(9-39) derivatives.
  • Synthesized and characterized three 68Ga-labeled derivatives (E09, E12, E27) with antagonist properties.
  • Validated binding affinities using surface plasmon resonance (SPR) and assessed in vivo performance via PET imaging.

Main Results:

  • MD simulations accurately predicted binding affinities, ranking E09 > E12 > E27.
  • [68Ga]Ga-E09 exhibited significantly higher tumor uptake (SUVmax: 3.99) compared to E12 (SUVmax: 0.75) and E27 (undetectable) in PET imaging.
  • All radiotracers demonstrated excellent radiochemical yields (>95%) and plasma stability (>91% intact).

Conclusions:

  • The combination of computational screening and experimental validation is effective for developing novel radiotracers.
  • [68Ga]Ga-E09 shows superior binding affinity, tumor uptake, and imaging characteristics, positioning it as a promising candidate for insulinoma imaging.
  • This novel antagonist tracer offers a potentially safer alternative for patients, particularly children, undergoing GLP-1R targeted imaging.